key: cord-0758530-383sp7f5
authors: Bakhshaliyev, Nijad; Uluganyan, Mahmut; Enhos, Asim; Karacop, Erdem; Ozdemir, Ramazan
title: The effect of 5-day course of hydroxychloroquine and azithromycin combination on QT interval in non-ICU COVID19(+) patients
date: 2020-08-11
journal: J Electrocardiol
DOI: 10.1016/j.jelectrocard.2020.08.008
sha: 2c3d85c2a0d08d8e40917e911118de40998caff6
doc_id: 758530
cord_uid: 383sp7f5

BACKGROUND: The combination of Hydroxychloroquine (HCQ) and azithromycin showed effectiveness as a treatment for COVID-19 and is being used widely all around the world. Despite that those drugs are known to cause prolonged QT interval individually there is no study assessing the impact of this combination on electrocardiography (ECG). This study aimed to assess the impact of a 5-day course of HCQ and azithromycin combination on ECG in non-ICU COVID19(+) patients. METHODS: In this retrospective observational study, we enrolled 109 COVID19(+) patients who required non-ICU hospitalization. All patients received 5-day protocol of HCQ and azithromycin combination. On-treatment ECGs were repeated 3-6 h after the second HCQ loading dose and 48-72 h after the first dose of the combination. ECGs were assessed in terms of rhythm, PR interval, QRS duration, QT and QTc intervals. Baseline and on-treatment ECG findings were compared. Demographic characteristics, laboratory results were recorded. Daily phone call-visit or bed-side visit were performed by attending physician. RESULTS: Of the 109 patients included in the study, the mean age was 57.3 ± 14.4 years and 48 (44%) were male. Mean baseline PR interval was 158.47 ± 25.10 ms, QRS duration was 94.00 ± 20.55 ms, QTc interval was 435.28 ± 32.78 ms, 415.67 ± 28.51, 412.07 ± 25.65 according to Bazett's, Fridericia's and Framingham Heart Study formulas respectively. ∆PR was −2.94 ± 19.93 ms (p = .55), ∆QRS duration was 5.18 ± 8.94 ms (p = .03). ∆QTc interval was 6.64 ± 9.60 ms (p = .5), 10.67 ± 9.9 ms (p = .19), 14.14 ± 9.68 ms (p = .16) according to Bazett's, Fridericia's and Framingham Heart Study formulas respectively. There were no statistically significant differences between QTc intervals. No ventricular tachycardia, ventricular fibrillation or significant conduction delay was seen during follow-up. There was no death or worsening heart function. CONCLUSION: The 5-day course of HCQ- AZM combination did not lead to clinically significant QT prolongation and other conduction delays compared to baseline ECG in non-ICU COVID19(+) patients.

Since reporting of the first case on December 9 in Wuhan, China, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread swiftly in a short time throughout China and the outside 1 . In early March World Health Organization (WHO) declared the SARS-CoV-2 outbreak a pandemic 2 . Due to the lack of specific antiviral medication for treatment and vaccine for prevention "repurposing" drugs emerged as a rescuer to deal with this problem. Several known molecules were started to be tested in different countries [3] [4] [5] . Hydroxychloroquine is an analogue of chloroquine and has been used as an antimalarial and antirheumatic drug 6 . Antiviral effects of HCQ had been demonstrated 7, 8 . In a recent study HCQ reinforced by azithromycin was associated significantly with viral load reduction in COVID19 (+) patients 3 .

there is no study assessing the impact of this combination on ECG 14 . In this study, we aimed to evaluate the ECG changes in COVID19(+) patients taking HCQ -AZM combination.

Study population. Our study was designed as a retrospective observational study. We screened the records of 196 COVID19(+) patients presented to our hospital between March 31 and April 16 and who were followed in inpatient wards and received HCQ -AZM combination therapy. Pregnancy, patients under 18 years and patients who did not have control ECG were exclusion criteria. After exclusion, we included 109 patients in the study. The flowchart was described in Figure 1 . Patients who had COVID19(+) with asymptomatic or mildly symptomatic (such as the upper respiratory infection) and without comorbidity followed in the outpatient clinic and excluded from the study. Patients with the lower respiratory infection (such as pneumonia or bronchitis), 1 and more comorbidity and age more than 64 years were hospitalized to inpatient ward if SpO2 is more than %90 and hemodynamically stable.

Baseline and control ECG were obtained. Control ECGs were repeated 3-6h after the second HCQ loading dose and 48-72h after the first dose of the combination. ECGs were assessed in terms of rhythm, PR interval, QRS duration, QT and QTc intervals. Baseline and control ECG findings were compared. Demographic characteristics, laboratory results were recorded. Daily phone call-visit or bed-side visit were performed by attending physician.

contraindications for HCQ/AZM combination were: 1) QTc > 500 msn (or >550 msn in bundle branch block) on the baseline ECG; 2) Hypersensitivity.

On the first day HCQ was loaded orally 400 mg b.i.d then 200 mg b.i.d was given for following 4 days. After 500 mg loading dose on the first day, AZM was continued 250 mg od for following 4 days. Enfluvir was received 75 mg bid until influenza was excluded. Hydroxychloroquine and azithromycin combination were given for 5 days if not any contraindications. After that, if the patient remained symptomatic other medications can be given.

Blood samples from all patients who required hospitalization were sent to the laboratory to check electrolytes, hemogram, acute phase reactants, kidney and liver functions, troponin I, creatinine kinasemyocardial band (CK-MB), and D-dimer. Demographic characteristics, concomitant diseases, medications were recorded.

All ECGs were recorded using Mortara ELI 250 device (Welch Allyn, Inc, Skaneateles Falls, NY, USA; standard 12-lead resting ECG, paper speed of 25 mm/s, the amplitude of 10 mm/V, and a sampling rate of 250 Hz). Patient's 12-lead ECGs were evaluated before starting HCQ and azithromycin combination. Control ECG was obtained 3 to 6 h after the second HCQ loading dose. QT measurement was performed in leads Ⅱ, V5 or V6. Measured longest QT interval was used. To exclude interobserver variability all measurements were completed by one cardiologist (NB). In case of problems with measurement, the second cardiologist (AE) measured blindly the QT interval to the first cardiologist. If discrepancy between these two cardiologists was more than %5, the third cardiologist (EK) were invited to resolve the problem. The PR interval was 

A total of 109 patients eligible for analysis fulfilled the following inclusion criteria: 1)

Patients who were in sinus rhythm; 2) Patients > 18 years and were followed in in-patient ward;

3) Patients who were started HCQ and azithromycin combination; 4) Patients who had at least 2 control ECGs during the treatment period. Exclusion criteria were: 1) cardiac rhythm other than sinus; 2) Early discharged patients; 3) patients whose combination treatment was changed due to course of the disease (other than cardiac or arrhythmic reasons); 4) Pregnancy. One hundred and nine patients were included in the study. Of them, 48 (44%) were male and the mean age was 57.3 ± 14.4 years ( (Table 3) . Compared with baseline QTc interval, QT prolongation ≥50 msn and QTc interval ≥ 500 msn was observed in 2 (1.8%) patients. We analyzed baseline QTc interval and ∆QTc according to serum potassium level (serum K + < 4.0 mmol/L vs. serum K + ≥ 4.0 mmol/L). In contrast to higher serum potassium level (K + ≥ 4.0 mmol/L), lower serum potassium level (serum K + < 4.0 mmol/L) were associated with statistically significantly longer QT interval. But no difference existed between ∆QTc interval in this subgroup. This may be related to potassium replacement in patients who had lower serum potassium level (serum K + < 4.0 mmol/L). Detailed results were demonstrated in Table 5 . No ventricular tachycardia, ventricular fibrillation or significant conduction delay was seen during follow-up. There was no death or worsening heart function. Two potassium ion channels, delayed rectifier K+ current (I kr (rapid) and I ks (slow)) primarily carry out myocardial repolarization. Virtually I kr was blocked by QT-prolonging drugs 17 Cardiomyopathy with azithromycin has been reported 21 .

Recently conducted chloroquine (CQ) study was stopped prematurely due to increased mortality rate with high dose CQ (the cumulative dose 12 g) in comparison to low dose (the cumulative dose 2.7 g) 22 . Hydroxychloroquine is less toxic than CQ 16 . In our study, there were no significant cardiac adverse effects with HCQ and it was well tolerated. Concomitantly, 75% of patients received oseltamivir and 8% favipiravir.

Azithromycin is a macrolide. Oral bioavailability is low and affected by foods. After taken 500 mg azithromycin orally it takes 2 h to reach serum peak concentration. Binding to plasma protein is low. Similar to other macrolides azithromycin interacts with the cytochrome P-450 and can influence other drugs metabolisms 23 . Hydroxychloroquine metabolizes by the cytochrome enzymes partly and this rises concern about drug interaction when used together. There were no significant interactions before in clinical practice 24 . In our study, there was no significant QT prolongation despite at least 68% of patients received three QT-prolonging medications.

Along with HCQ/AZM, 7 (6.4%) patients were received SSRI, 1 (0.9%) patient received amiodarone and 1 (0.9%) patient received ranolazine. No difference was observed on ECGs of these patients compared to other patients.

Azithromycin is known as the safest macrolide in terms of cardiac events 25 , this can be derived from unique monophasic action potential configuration compared with clarithromycin and erythromycin. But conflicting studies exist regarding the cardiovascular safety of azithromycin 26 .

The QT prolongation and proarrhythmic effects that were reported previously were induced by antibiotics azithromycin was safe and did not increase cardiac arrhythmias and heart failure among older population 30 . In Danish adult cohort study, azithromycin was not associated with increased cardiovascular risk as compared with penicillin V in young and middle-aged adults 31 .

There are some limitations to our study. The sample size was small and designed as a single center study. We could not compare our outcomes with other protocols. The QT interval can be affected by several factors including medications, metabolic status, hypoxia, ischemia and underlying pathologies. Patients who were followed in the intensive care unit and who was intubated can be susceptible to QT-prolonging medications. Hence our results should not be generalized to all patients who are a candidate for HCQ and azithromycin combination. We did not perform a power analysis to calculate sample size that we need to predict the prevalence of significant QT prolongation following HCQ and azithromycin combination. However, our study demonstrated that prolonged QT interval after HCQ and azithromycin loading dose generally shortened during the maintenance period. By increasing the number of patients and centers attended the study, our results need to be confirmed.

The 5-day course of HCQ -AZM combination did not lead to significant QT prolongation and other conduction delays compared to baseline ECG in non-ICU COVID19(+) patients.

J o u r n a l P r e -p r o o f 14.14 ± 9.68 

A novel coronavirus from patients with pneumonia in China

WHO Director-General's opening remarks at the media briefing on COVID-19-11

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro

Discovering drugs to treat coronavirus disease 2019 (COVID-19)

Hydroxychloroquine: from malaria to autoimmunity

Inhibition of HIV-1 replication by hydroxychloroquine: mechanism of action and comparison with zidovudine

Hydroxychloroquine-inhibited dengue virus is associated with host defense machinery

Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia

Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors

Azithromycin and the risk of cardiovascular death

Association of polymorphisms of cytochrome P450 2D6 with blood hydroxychloroquine levels in patients with systemic lupus erythematosus

Comparing two types of macrolide antibiotics for the purpose of assessing population-based drug interactions

Considerations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus Disease 2019) Treatment. Circulation

Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management

Insights from pharmacokinetic and pharmacodynamic studies of hydroxychloroquine

Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes

Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death

Severe hydroxychloroquine poisoning reversed with diazepam

Hypokalaemia related to acute chloroquine ingestion

Hydroxychloroquine-induced cardiomyopathy: case report, pathophysiology, diagnosis, and treatment

Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, doubleblinded, phase IIb clinical trial (CloroCovid-19 Study)

The pharmacokinetics of azithromycin and their clinical significance

Antimicrobial-associated QT interval prolongation: pointes of interest

Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes

Azithromycin-induced torsade de pointes

Azithromycin-induced QT prolongation in elderly patient

A case of QT-interval prolongation precipitated by azithromycin

Association of Azithromycin With Mortality and Cardiovascular Events Among Older Patients Hospitalized With Pneumonia

Use of Azithromycin and Death from Cardiovascular Causes

Serum creatinine, mg/dL

Serum potassium, mmol/L

Serum calcium, mg/dL

Serum magnesium, mg/dL

Serum natrium, mmol/L, mean ± SD

ESR, mm/h, median (IQR)

BUN-blood urine nitrogen; CRP-C reactive protein; ESR-erythrocyte sedimentation rate; IQRinterquartile range; SD-standard deviation

Gender, M, n (%) 48 (44) Age, year, mean ± SD 57. 3 ± 14.4 Hypertension, n (%) 49 (45) DM, n (%) 32 (29.4) CAD, n (%) 24 (22) HFrEF or HFpEF, n (%) 10 (9. ECG-electrocardiogram; LBBB-left bundle branch block; NIVCD -Nonspecific intraventricular conduction delay; QTc-corrected QT; RBBB-right bundle branch block; SD-standard deviation J o u r n a l P r e -p r o o f